Advertisement

International Journal of Hematology

, Volume 107, Issue 6, pp 681–688 | Cite as

Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan

  • Ayako Kamiunten
  • Kotaro Shide
  • Takuro Kameda
  • Masaaki Sekine
  • Yoko Kubuki
  • Masafumi Ito
  • Takanori Toyama
  • Noriaki Kawano
  • Kousuke Marutsuka
  • Kouichi Maeda
  • Masanori Takeuchi
  • Hiroshi Kawano
  • Seiichi Sato
  • Junzo Ishizaki
  • Keiichi Akizuki
  • Yuki Tahira
  • Haruko Shimoda
  • Tomonori Hidaka
  • Kiyoshi Yamashita
  • Hitoshi Matsuoka
  • Kazuya Shimoda
Original Article

Abstract

Polycythemia vera (PV) and essential thrombocythemia (ET) are associated with life-threatening thrombohemorrhagic events, and disease progression and development of non-hematological malignancies also reduce long-term survival. We retrospectively surveyed thrombohemorrhagic events and overall survival (OS) in 62 PV and 117 ET patients. The cumulative incidences of thrombohemorrhagic events in PV and ET patients were 11.3 and 10.3%, and the incidence rates were 2.42 and 1.85 per 100 person-years. The combined incidence rates of disease progression and development of non-hematological malignancies in PV and ET patients were 1.73 and 1.69 per 100 person-years. The incidence rates of thrombohemorrhagic events in our Japanese PV/ET patients were lower than those reported by most Western studies, but were comparable to those in the largest prospective observational study in ET patients. The combined incidence rates of disease progression and development of non-hematological malignancies were similar between Japanese and Western PV/ET patients. In ET patients, the conventional risk stratification model based on the presence of advanced age or history of thrombosis was useful to predict thrombosis risk, and both the conventional model and the International Prognostic Score of thrombosis in ET based on the above 2 risk factors plus increased leukocyte count could predict poor survival.

Keywords

Polycythemia vera (PV) Essential thrombocythemia (ET) Thrombohemorrhagic events Prognosis 

Notes

Compliance with ethical standards

Conflict of interest

We have no financial relationships to disclose.

References

  1. 1.
    Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.CrossRefPubMedGoogle Scholar
  2. 2.
    Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–90.CrossRefPubMedGoogle Scholar
  3. 3.
    James C, Ugo V, Le Couédic J-P, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.CrossRefPubMedGoogle Scholar
  5. 5.
    Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.CrossRefPubMedGoogle Scholar
  6. 6.
    Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel JP, Mermel CH, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014;123:e123–33.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379–90.CrossRefPubMedGoogle Scholar
  8. 8.
    Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–405.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Imai M, Araki M, Komatsu N. Somatic mutations of calreticulin in myeloproliferative neoplasms. Int J Hematol. 2017;105:743–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, Derolf AR, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012;30:2995–3001.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224–32.CrossRefPubMedGoogle Scholar
  13. 13.
    Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012;120:1197–201.CrossRefPubMedGoogle Scholar
  14. 14.
    Yesilova AM, Yavuzer S, Yavuzer H, Cengiz M, Toprak ID, Hanedar E, et al. Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study. Int J Hematol. 2017;105:70–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Barbui T, Finazzi G. Evidence-based management of polycythemia vera. Best Pract Res Clin Haematol. 2006;19:483–93.CrossRefPubMedGoogle Scholar
  16. 16.
    Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123:656–64.CrossRefGoogle Scholar
  17. 17.
    Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128:275–90.CrossRefPubMedGoogle Scholar
  18. 18.
    Landolfi R, Di Gennaro L. Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica. 2008;93:331–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90:162–73.CrossRefPubMedGoogle Scholar
  20. 20.
    Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22–33.CrossRefPubMedGoogle Scholar
  21. 21.
    Cortelazzo S, Viero P, Finazzi G, D’Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8:556–62.CrossRefPubMedGoogle Scholar
  22. 22.
    Besses C, Cervantes F, Pereira A, Florensa L, Sole F, Hernandez-Boluda JC, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia. 1999;13:150–4.CrossRefPubMedGoogle Scholar
  23. 23.
    Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29:761–70.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Usui N. JSH guideline for tumors of hematopoietic and lymphoid tissues—lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN). Int J Hematol. 2017;106:591–611.CrossRefPubMedGoogle Scholar
  25. 25.
    Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120:5128–33 (quiz 252).CrossRefPubMedGoogle Scholar
  26. 26.
    Pearson TC, Messinezy M. The diagnostic criteria of polycythaemia rubra vera. Leuk Lymphoma. 1996;22(Suppl 1):87–93.PubMedGoogle Scholar
  27. 27.
    Swerdlow, S.H. et al. (ed.). WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008, p 40–50.Google Scholar
  28. 28.
    Jaffe, E.S. et al. (ed.). World Health Organization classification of tumors. Lyon: IARC Press; 2001, pp 230–235.Google Scholar
  29. 29.
    Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5:e369.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Edahiro Y, Morishita S, Takahashi K, Hironaka Y, Yahata Y, Sunami Y, et al. JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan. Int J Hematol. 2014;99:625–34.CrossRefPubMedGoogle Scholar
  31. 31.
    Okabe M, Yamaguchi H, Usuki K, Kobayashi Y, Kawata E, Kuroda J, et al. Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations. Leuk Res. 2016;40:68–76.CrossRefPubMedGoogle Scholar
  32. 32.
    Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459–68.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Dan K, Yamada T, Kimura Y, Usui N, Okamoto S, Sugihara T, et al. Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group. Int J Hematol. 2006;83:443–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Di Nisio M, Barbui T, Di Gennaro L, Borrelli G, Finazzi G, Landolfi R, et al. The haematocrit and platelet target in polycythemia vera. Br J Haematol. 2007;136:249–59.CrossRefPubMedGoogle Scholar
  35. 35.
    Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013;121:1720–8.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Birgegard G, Besses C, Griesshammer M, Gugliotta L, Harrison CN, Hamdani M, et al. Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the EXELS study. Haematologica. 2018;103:51–60.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015;5:e366.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Barbui T, Thiele J, Vannucchi AM, Tefferi A. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia. 2013;27:1953–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Thiele J, Kvasnicka HM, Mullauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood. 2011;117:5710–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179–84.CrossRefPubMedGoogle Scholar
  41. 41.
    Montanaro M, Latagliata R, Cedrone M, Spadea A, Rago A, Di Giandomenico J, et al. Thrombosis and survival in essential thrombocythemia: a regional study of 1,144 patients. Am J Hematol. 2014;89:542–6.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  • Ayako Kamiunten
    • 1
  • Kotaro Shide
    • 1
  • Takuro Kameda
    • 1
  • Masaaki Sekine
    • 1
  • Yoko Kubuki
    • 1
  • Masafumi Ito
    • 2
  • Takanori Toyama
    • 3
  • Noriaki Kawano
    • 4
  • Kousuke Marutsuka
    • 4
  • Kouichi Maeda
    • 5
  • Masanori Takeuchi
    • 6
  • Hiroshi Kawano
    • 6
  • Seiichi Sato
    • 7
  • Junzo Ishizaki
    • 8
  • Keiichi Akizuki
    • 1
  • Yuki Tahira
    • 1
  • Haruko Shimoda
    • 1
  • Tomonori Hidaka
    • 1
  • Kiyoshi Yamashita
    • 4
  • Hitoshi Matsuoka
    • 6
  • Kazuya Shimoda
    • 1
  1. 1.Department of Gastroenterology and Hematology, Faculty of MedicineUniversity of MiyazakiMiyazakiJapan
  2. 2.Japanese Red Cross Nagoya Daiichi HospitalNagoyaJapan
  3. 3.Miyazaki Prefectural Nobeoka HospitalNobeokaJapan
  4. 4.Miyazaki Prefectural Miyazaki HospitalMiyazakiJapan
  5. 5.Miyakonojo Medical CenterMiyakonojoJapan
  6. 6.Koga General HospitalMiyazakiJapan
  7. 7.Fujimoto General HospitalMiyakonojoJapan
  8. 8.Miyazaki Aisenkai Nichinan HospitalNichinanJapan

Personalised recommendations